Angiogenesis, a key process for the growth of human cancers, has recently been exploited
for the development of a novel class of cancer therapeutics that was thought to have wide
applications and not to induce resistance in the clinical setting. Indeed, anti-angiogenic
therapy has become an important option for the management of several human
malignancies. However, a significant number of patients either do not respond to anti-
angiogenic agents or fairly rapidly develop resistance. In addition, the benefit of anti …